Transforming Medicine with Next-Gen AI

Pharmatech AI is a company using artificial intelligence to transform how new drugs are discovered, especially in areas like pain relief and cannabinoid research. Their goal is to speed up and lower the cost of developing new drug combinations, making healthcare innovation more accessible.

They develop the AI Multi-Drug Interaction Predictor (AI-MDIP), a high-tech AI model that predicts how different drugs interact, including cannabis compounds, using Graph Neural Networks. They also grow cannabis in their own lab to create unique data, giving them an edge over competitors.

The PCH token, with a fixed supply of 1 billion, is used for bidding on drug licenses, staking to earn revenue shares in stablecoins, voting on project decisions, and community rewards. A buy-back-and-burn strategy reduces the token supply, potentially increasing its value over time.

The global drug discovery market is expected to reach $137.72 billion by 2029, AI in drug discovery $7.1 billion by 2030, and medical cannabis $41.4 billion by 2030. We plan to earn $15 million from licensing by 2027 and $15 million yearly from subscriptions by 2028.

By holding PCH tokens, investors can stake them to receive 70% of platform revenues quarterly in stablecoins, benefit from the buy-back-and-burn value growth, and use tokens for ecosystem activities. They can also influence project decisions through governance voting.